DACH1 inhibits cyclin D1 expression, cellular proliferation and tumor growth of renal cancer cells

详细信息    查看全文

• 作者：Qian Chu (1)
  Na Han (1)
  Xun Yuan (1)
  Xin Nie (1)
  Hua Wu (1)
  Yu Chen (1)
  Mingzhou Guo (2)
  Shiying Yu (1)
  Kongming Wu (1)
  
  1. Department of Oncology ; Tongji Hospital ; Tongji Medical College of Huazhong University of Science and Technology ; 1095 Jiefang Avenue ; Wuhan ; Hubei ; 430030 ; China
  2. Department of Gastroenterology & Hepatology ; Chinese PLA General Hospital ; #28 Fuxing Road ; Beijing ; 100853 ; China
  
• 关键词：Renal carcinoma ; DACH1 ; Tumor growth ; Proliferation ; Cell cycle ; Cyclin D1
• 刊名：Journal of Hematology & Oncology
• 出版年：2014
• 出版时间：December 2014
• 年：2014
• 卷：7
• 期：1
• 全文大小：1,370 KB
• 参考文献：1. De P, Otterstatter MC, Semenciw R, Ellison LF, Marrett LD: Dryer D Trends in incidence, mortality, and survival for kidney cancer in Canada, 1986鈥?007. / Cancer Causes Control 2014 [Epub ahead of print].
  2. Santoni, M, Tursi, M, Felici, A, Lo Re, G, Ricotta, R, Ruggeri, EM, Sabbatini, R, Santini, D, Vaccaro, V, Milella, M (2013) Management of metastatic renal cell carcinoma patients with poor-risk features: current status and future perspectives. Expert Rev Anticancer Ther 13: pp. 697-709 CrossRef
  3. Hudes, G, Carducci, M, Tomczak, P, Dutcher, J, Figlin, R, Kapoor, A, Staroslawska, E, Sosman, J, McDermott, D, Bodrogi, I, Kovacevic, Z, Lesovoy, V, Schmidt-Wolf, IG, Barbarash, O, Gokmen, E, O鈥橳oole, T, Lustgarten, S, Moore, L, Motzer, RJ (2007) Global ARCC Trial. temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356: pp. 2271-2281 CrossRef
  4. Motzer, RJ, Molina, AM (2009) Targeting renal cell carcinoma. J Clin Oncol 27: pp. 3274-3276 CrossRef
  5. Iacovelli, R, Alesini, D, Palazzo, A, Trenta, P, Santoni, M, Marchis, L, Cascinu, S, Naso, G, Cortesi, E (2014) Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. a meta-analysis of published trials. Cancer Treat Rev 40: pp. 271-275 CrossRef
  6. Finley, DS, Pantuck, AJ, Belldegrun, AS (2011) Tumor biology and prognostic factors in renal cell carcinoma. Oncologist 16: pp. 4-13 CrossRef
  7. Koul, H, Huh, JS, Rove, KO, Crompton, L, Koul, S, Meacham, RB, Kim, FJ (2011) Molecular aspects of renal cell carcinoma: a review. Am J Cancer Res 1: pp. 240-254
  8. Hu, C, Mohtat, D, Yu, Y, Ko, YA, Shenoy, N, Bhattacharyya, S, Izquierdo, MC, Park, AS, Giricz, O, Vallumsetla, N, Gundabolu, K, Ware, K, Bhagat, T, Suzuki, M, Pullman, J, Liu, SX, Greally, J, Susztak, K, Verma, A (2014) Kidney cancer is characterized by aberrant methylation of tissue specific enhancers that are prognostic for overall survival. Clin Cancer Res 20: pp. 4349-4360 CrossRef
  9. Dalgin, GS, Drever, M, Williams, T, King, T, DeLisi, C, Liou, LS (2008) Identification of novel epigenetic markers for clear cellrenal cell carcinoma. J Urol 180: pp. 1126-1130 CrossRef
  10. Atkins, M, Jiang, Y, Sansores-Garcia, L, Jusiak, B, Halder, G, Mardon, G (2013) Dynamic rewiring of the Drosophila retinal determination network switches its function from selector to differentiation. PLoS Genet 9: pp. e1003731 CrossRef
  11. Li, X, Oghi, KA, Zhang, J, Krones, A, Bush, KT, Glass, CK, Nigam, SK, Aggarwal, AK, Maas, R, Rose, DW, Rosenfeld, MG (2003) Eya protein phosphatase activity regulates Six1-Dach-Eya transcriptional effects in mammalian organogenesis. Nature 426: pp. 247-254 CrossRef
  12. Popov, VM, Wu, K, Zhou, J, Powell, MJ, Mardon, G, Wang, C, Pestell, RG (2010) The Dachshund gene in development and hormone-responsive tumorigenesis. Trends Endocrinol Metab 21: pp. 41-49 CrossRef
  13. Wu W, Ren Z, Li P, Yu D, Chen J, Huang R, Liu H: Six1: A critical transcription factor in tumorigenesis. / Int J Cancer 2014 doi: 10.1002/ijc.28755. [Epub ahead of print].
  14. Tadjuidje, E, Hegde, RS (2013) The Eyes Absent proteins in development and disease. Cell Mol Life Sci 70: pp. 1897-1913 CrossRef
  15. Wu, K, Li, A, Rao, M, Liu, M, Dailey, V, Yang, Y, Vizio, D, Wang, C, Lisanti, MP, Sauter, G, Russell, RG, Cvekl, A, Pestell, RG (2006) DACH1 is a cell fate determination factor that inhibits cyclin D1 and breast tumor growth. Mol Cell Biol 26: pp. 7116-7129 CrossRef
  16. Wu, K, Katiyar, S, Witkiewicz, A, Li, A, McCue, P, Song, LN, Tian, L, Jin, M, Pestell, RG (2009) The cell fate determination factor dachshund inhibits androgen receptor signaling and prostate cancer cellular growth. Cancer Res 69: pp. 3347-3355 CrossRef
  17. Wu, K, Katiyar, S, Li, A, Liu, M, Ju, X, Popov, VM, Jiao, X, Lisanti, MP, Casola, A, Pestell, RG (2008) Dachshund inhibits oncogene-induced breast cancer cellular migration and invasion through suppression of interleukin-8. Proc Natl Acad Sci U S A 105: pp. 6924-6929 CrossRef
  18. Zhou, J, Wang, C, Wang, Z, Dampier, W, Wu, K, Casimiro, MC, Chepelev, I, Popov, VM, Quong, A, Tozeren, A, Zhao, K, Lisanti, MP, Pestell, RG (2010) Attenuation of Forkhead signaling by the retinal determination factor DACH1. Proc Natl Acad Sci U S A 107: pp. 6864-6869 CrossRef
  19. Watanabe, A, Ogiwara, H, Ehata, S, Mukasa, A, Ishikawa, S, Maeda, D, Ueki, K, Ino, Y, Todo, T, Yamada, Y, Fukayama, M, Saito, N, Miyazono, K, Aburatani, H (2011) Homozygously deleted gene DACH1 regulates tumor-initiating activity of glioma cells. Proc Natl Acad Sci U S A 108: pp. 12384-12389 CrossRef
  20. Zhu, H, Wu, K, Yan, W, Hu, L, Yuan, J, Dong, Y, Li, Y, Jing, K, Yang, Y, Guo, M (2013) Epigenetic silencing of DACH1 induces loss of transforming growth factor-尾1 antiproliferative response in human hepatocellular carcinoma. Hepatology 58: pp. 2012-2022 CrossRef
  21. Chen, K, Wu, K, Cai, S, Zhang, W, Zhou, J, Wang, J, Ertel, A, Li, Z, Rui, H, Quong, A, Lisanti, MP, Tozeren, A, Tanes, C, Addya, S, Gormley, M, Wang, C, McMahon, SB, Pestell, RG (2013) Dachshund binds p53 to block the growth of lung adenocarcinoma cells. Cancer Res 73: pp. 3262-3274 CrossRef
  22. Yan W, Wu K, Herman JG, Brock MV, Zhou Y, Lu Y, Zhang Z, Yang Y, Guo M: Epigenetic silencing of DACH1 induces the invasion and metastasis of gastric cancer by activating TGF-尾 signalling. / J Cell Mol Med 2014 doi: 10.1111/jcmm.12325. [Epub ahead of print].
  23. Wu, K, Chen, K, Wang, C, Jiao, X, Wang, L, Zhou, J, Wang, J, Li, Z, Addya, S, Sorensen, PH, Lisanti, MP, Quong, A, Ertel, A, Pestell, RG (2014) Cell fate factor DACH1 represses YB-1-mediated oncogenic transcription and translation. Cancer Res 74: pp. 829-839 CrossRef
  24. Wu, K, Li, Z, Cai, S, Tian, L, Chen, K, Wang, J, Hu, J, Sun, Y, Li, X, Ertel, A, Pestell, RG (2013) EYA1 phosphatase function is essential to drive breast cancer cell proliferation through cyclin D1. Cancer Res 73: pp. 4488-4499 CrossRef
  25. Micalizzi, DS, Christensen, KL, Jedlicka, P, Coletta, RD, Bar贸n, AE, Harrell, JC, Horwitz, KB, Billheimer, D, Heichman, KA, Welm, AL, Schiemann, WP, Ford, HL (2009) The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-beta signaling. J Clin Invest 119: pp. 2678-2690 CrossRef
  26. Iwanaga, R, Wang, CA, Micalizzi, DS, Harrell, JC, Jedlicka, P, Sartorius, CA, Kabos, P, Farabaugh, SM, Bradford, AP, Ford, HL (2012) Expression of Six1 in luminal breast cancers predicts poor prognosis and promotes increases in tumor initiating cells by activation of extracellular signal-regulated kinase and transforming growth factor-beta signaling pathways. Breast Cancer Res 14: pp. R100 CrossRef
  27. McCoy, EL, Iwanaga, R, Jedlicka, P, Abbey, NS, Chodosh, LA, Heichman, KA, Welm, AL, Ford, HL (2009) Six1 expands the mouse mammary epithelial stem/progenitor cell pool and induces mammary tumors that undergo epithelial-mesenchymal transition. J Clin Invest 119: pp. 2663-2677 CrossRef
  28. Farabaugh, SM, Micalizzi, DS, Jedlicka, P, Zhao, R, Ford, HL (2012) Eya2 is required to mediate the pro-metastatic functions of Six1 via the induction of TGF-尾 signaling, epithelial-mesenchymal transition, and cancer stem cell properties. Oncogene 31: pp. 552-562
  29. Powe, DG, Dhondalay, GK, Lemetre, C, Allen, T, Habashy, HO, Ellis, IO, Rees, R, Ball, GR (2014) DACH1: its role as a classifier of long term good prognosis in luminal breast cancer. PLoS One 9: pp. e84428 CrossRef
  30. Kozmik, Z, Pfeffer, P, Kralova, J, Paces, J, Paces, V, Kalousova, A, Cvekl, A (1999) Molecular cloning and expression of the human and mouse homologues of the Drosophila dachshund gene. Dev Genes Evol 209: pp. 537-545 CrossRef
  31. Yan, W, Wu, K, Herman, JG, Brock, MV, Fuks, F, Yang, L, Zhu, H, Li, Y, Yang, Y, Guo, M (2013) Epigenetic regulation of DACH1, a novel Wnt signaling component in colorectal cancer. Epigenetics 8: pp. 1373-1383 CrossRef
  32. Wu, L, Herman, JG, Brock, MV, Wu, K, Mao, G, Yan, W, Nie, Y, Liang, H, Zhan, Q, Li, W, Guo, M (2014) Silencing DACH1 promotes esophageal cancer growth by inhibiting TGF-尾 signaling. PLoS One 9: pp. e95509 CrossRef
  33. Wu, K, Liu, M, Li, A, Donninger, H, Rao, M, Jiao, X, Lisanti, MP, Cvekl, A, Birrer, M, Pestell, RG (2007) Cell fate determination factor DACH1 inhibits c-Jun-induced contact-independent growth. Mol Biol Cell 18: pp. 755-767 CrossRef
  34. Coletta, RD, Christensen, K, Reichenberger, KJ, Lamb, J, Micomonaco, D, Huang, L, Wolf, DM, M眉ller-Tidow, C, Golub, TR, Kawakami, K, Ford, HL (2004) The Six1 homeoprotein stimulates tumorigenesis by reactivation of cyclin A1. Proc Natl Acad Sci U S A 101: pp. 6478-6483 CrossRef
  35. Yu, Y, Davicioni, E, Triche, TJ, Merlino, G (2006) The homeoprotein six1 transcriptionally activates multiple protumorigenic genes but requires ezrin to promote metastasis. Cancer Res 66: pp. 1982-1989 CrossRef
  36. Tan, J, Cang, S, Ma, Y, Petrillo, RL, Liu, D (2010) Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol 3: pp. 5 CrossRef
  37. Roy, S, Levi, E, Majumdar, AP, Sarkar, FH (2012) Expression of miR-34 is lost in colon cancer which can be re-expressed by a novel agent CDF. J Hematol Oncol 5: pp. 58 CrossRef
  38. Wu, K, Jiao, X, Li, Z, Katiyar, S, Casimiro, MC, Yang, W, Zhang, Q, Willmarth, NE, Chepelev, I, Crosariol, M, Wei, Z, Hu, J, Zhao, K, Pestell, RG (2011) Cell fate determination factor Dachshund reprograms breast cancer stem cell function. J Biol Chem 286: pp. 2132-2142 CrossRef
  39. Zatyka, M, Silva, NF, Clifford, SC, Morris, MR, Wiesener, MS, Eckardt, KU, Houlston, RS, Richards, FM, Latif, F, Maher, ER (2002) Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease. Cancer Res 62: pp. 3803-3811
  40. Hedberg, Y, Ljungberg, B, Roos, G, Landberg, G (2003) Expression of cyclin D1, D3, E, and p27 in human renal cell carcinoma analysed by tissue microarray. Br J Cancer 88: pp. 1417-1423 CrossRef
  41. Bai, L, Yang, JC, Ok, JH, Mack, PC, Kung, HJ, Evans, CP (2012) Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration. Int J Cancer 130: pp. 2693-2702 CrossRef
  42. Yuen, JS, Sim, MY, Siml, HG, Chong, TW, Lau, WK, Cheng, CW, Huynh, H (2011) Inhibition of angiogenic and non-angiogenic targets by sorafenib in renal cell carcinoma (RCC) in a RCC xenograft model. Br J Cancer 104: pp. 941-947 CrossRef
  43. Liu, J, Li, M, Song, B, Jia, C, Zhang, L, Bai, X, Hu, W (2013) Metformin inhibits renal cell carcinoma in vitro and in vivo xenograft. Urol Oncol 31: pp. 264-270 CrossRef
  44. Miyake, M, Goodison, S, Lawton, A, Zhang, G, Gomes-Giacoia, E, Rosser, CJ (2013) Erythropoietin is a JAK2 and ERK1/2 effector that can promote renal tumor cell proliferation under hypoxic conditions. J Hematol Oncol 6: pp. 65 CrossRef
  45. Hedberg, Y, Davoodi, E, Roos, G, Ljungberg, B, Landberg, G (1999) Cyclin-D1 expression in human renal-cell carcinoma. Int J Cancer 84: pp. 268-272 CrossRef
  46. Jeselsohn, R, Brown, NE, Arendt, L, Klebba, I, Hu, MG, Kuperwasser, C, Hinds, PW (2010) Cyclin D1 kinase activity is required for the self-renewal of mammary stem and progenitor cells that are targets of MMTV-ErbB2 tumorigenesis. Cancer Cell 17: pp. 65-76 CrossRef
  47. Pestell, RG, Li, Z (2006) Antisense to cyclin D1 inhibits VEGF-stimulated growth of vascular endothelial cells: implication of tumor vascularization. Clin Cancer Res 12: pp. 4459-4462 CrossRef
  48. Casimiro, MC, Crosariol, M, Loro, E, Ertel, A, Yu, Z, Dampier, W, Saria, EA, Papanikolaou, A, Stanek, TJ, Li, Z, Wang, C, Fortina, P, Addya, S, Tozeren, A, Knudsen, ES, Arnold, A, Pestell, RG (2012) ChIP sequencing of cyclin D1 reveals a transcriptional role in chromosomal instability in mice. J Clin Invest 122: pp. 833-843 CrossRef
  49. Saha, MN, Qiu, L, Chang, H (2013) Targeting p53 by small molecules in hematological malignancies. J Hematol Oncol 6: pp. 23 CrossRef
  50. Wu, K, Yang, Y, Wang, C, Davoli, MA, D鈥橝mico, M, Li, A, Cveklova, K, Kozmik, Z, Lisanti, MP, Russell, RG, Cvekl, A, Pestell, RG (2003) DACH1 inhibits transforming growth factor-beta signaling through binding Smad4. J Biol Chem 278: pp. 51673-51684 CrossRef
  51. Chen, DL, Zeng, ZL, Yang, J, Ren, C, Wang, DS, Wu, WJ, Xu, RH (2013) L1cam promotes tumor progression and metastasis and is an independent unfavorable prognostic factor in gastric cancer. J Hematol Oncol 6: pp. 43 CrossRef
  52. Shi, K, Jiang, Q, Li, Z, Shan, L, Li, F, An, J, Yang, Y, Xu, C (2013) Sodium selenite alters microtubule assembly and induces apoptosis in vitro and in vivo. J Hematol Oncol 6: pp. 7 CrossRef
  53. Dong, LH, Cheng, S, Zheng, Z, Wang, L, Shen, Y, Shen, ZX, Chen, SJ, Zhao, WL (2013) Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphoma. J Hematol Oncol 6: pp. 53 CrossRef
  
• 刊物主题：Oncology; Hematology; Cancer Research;
• 出版者：BioMed Central
• ISSN：1756-8722

文摘

Background Renal cell carcinoma (RCC) is a complex with diverse biological characteristics and distinct molecular signature. New target therapies to molecules that drive RCC initiation and progression have achieved promising responses in some patients, but the total effective rate is still far from satisfaction. Dachshund (DACH1) network is a key signaling pathway for kidney development and has recently been identified as a tumor suppressor in several cancer types. However, its role in renal cell carcinoma has not been fully investigated. Methods Immunohistochemical staining for DACH1, PCNA and cyclin D1 was performed on human renal tissue microaraays and correlation with clinic-pathological characteristics was analyzed. In vitro proliferation, apoptosis and in vivo tumor growth were evaluated on human renal cancer cell lines with decitabine treatment or ectopic expression of DACH1. Downstream targets and potential molecular mechanism were investigated through western blot, immunoprecipitation and reporter gene assays. Results Expression of DACH1 was significantly decreased in human renal carcinoma tissue. DACH1 protein abundance was inversely correlated with the expression of PCNA and cyclin D1, tumor grade, and TNM stage. Restoration of DACH1 function in renal clear cell cancer cells inhibited in vitro cellular proliferation, S phase progression, clone formation, and in vivo tumor growth. In mechanism, DACH1 repressed cyclin D1 transcription through association with AP-1 protein. Conclusion Our results indicated that DACH1 was a novel molecular marker of RCC and it attributed to the malignant behavior of renal cancer cells. Re-activation of DACH1 may represent a potential therapeutic strategy.